Schröder FH - Search Results

1

Prostate cancer detection at low prostate specific antigen.

Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Schröder FH, et al. J Urol. 2000 Mar;163(3):806-12. J Urol. 2000. PMID: 10687982 Clinical Trial.

2

The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men.

Bangma CH, Kranse R, Blijenberg BG, Schröder FH. Bangma CH, et al. Among authors: schroder fh. Urology. 1995 Dec;46(6):773-8. doi: 10.1016/S0090-4295(99)80342-2. Urology. 1995. PMID: 7502414

3

The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.

Bangma CH, Kranse R, Blijenberg BG, Schröder FH. Bangma CH, et al. Among authors: schroder fh. Urology. 1995 Dec;46(6):779-84. doi: 10.1016/S0090-4295(99)80343-4. Urology. 1995. PMID: 7502415

4

Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism.

Bosch JL, Kranse R, van Mastrigt R, Schröder FH. Bosch JL, et al. Among authors: schroder fh. J Urol. 1995 Mar;153(3 Pt 1):689-93. doi: 10.1097/00005392-199503000-00039. J Urol. 1995. PMID: 7532234 Free article.

5

Dependence of male voiding efficiency on age, bladder contractility and urethral resistance: development of a voiding efficiency nomogram.

Bosch JL, Kranse R, van Mastrigt R, Schröder FH. Bosch JL, et al. Among authors: schroder fh. J Urol. 1995 Jul;154(1):190-4. doi: 10.1097/00005392-199507000-00059. J Urol. 1995. PMID: 7776421 Free article.

6

European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot studies.

Schröder FH, Denis LJ, Kirkels W, de Koning HJ, Standaert B. Schröder FH, et al. Cancer. 1995 Jul 1;76(1):129-34. doi: 10.1002/1097-0142(19950701)76:1<129::aid-cncr2820760120>3.0.co;2-1. Cancer. 1995. PMID: 8630864 Clinical Trial.

7

Some analytical considerations on the measurement of prostate-specific antigen.

Blijenberg BG, Kranse R, Eman I, Schröder FH. Blijenberg BG, et al. Among authors: schroder fh. Eur J Clin Chem Clin Biochem. 1996 Oct;34(10):817-21. doi: 10.1515/cclm.1996.34.10.817. Eur J Clin Chem Clin Biochem. 1996. PMID: 8933105

8

The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma.

Bangma CH, Kranse R, Blijenberg BG, Schröder FH. Bangma CH, et al. Among authors: schroder fh. J Urol. 1997 Feb;157(2):544-7. J Urol. 1997. PMID: 8996352

9

Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate.

van den Ouden D, Hop WC, Kranse R, Schröder FH. van den Ouden D, et al. Among authors: schroder fh. Br J Urol. 1997 Feb;79(2):203-11. doi: 10.1046/j.1464-410x.1997.33011.x. Br J Urol. 1997. PMID: 9052471

10

Analytical evaluation of the new Prostatus PSA Free/Total assay for prostate-specific antigen as part of a screening study for prostate cancer.

Blijenberg BG, Bangma CH, Kranse R, Eman I, Schröder FH. Blijenberg BG, et al. Among authors: schroder fh. Eur J Clin Chem Clin Biochem. 1997 Feb;35(2):111-4. Eur J Clin Chem Clin Biochem. 1997. PMID: 9056753 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

606 results

Search Page

Filters